Therapies with CCL25 require controlled release via microparticles to avoid strong inflammatory reactions

BACKGROUND: Chemokine therapy with C–C motif chemokine ligand 25 (CCL25) is currently under investigation as a promising approach to treat articular cartilage degeneration. We developed a delayed release mechanism based on Poly (lactic-co-glycolic acid) (PLGA) microparticle encapsulation for intraar...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinnen, J., Fröhlich, K., Sinner, N., Stolk, M., Ringe, J., Shopperly, L., Sittinger, M., Dehne, T., Seifert, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992824/
https://www.ncbi.nlm.nih.gov/pubmed/33766057
http://dx.doi.org/10.1186/s12951-021-00830-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992824/
https://www.ncbi.nlm.nih.gov/pubmed/33766057
http://dx.doi.org/10.1186/s12951-021-00830-7

Ejemplares similares